Navigation Links
Spitfire Pharma, Inc. will present body weight, liver weight and glucose regulation data on the GLP-1/Glucagon Dual Agonist SP-1373 at the American Diabetes Association's 77th Scientific Sessions
Date:4/11/2017

SOUTH SAN FRANCISCO, Calif., April 11, 2017 /PRNewswire/ -- Spitfire Pharma, Inc., ("Spitfire") is pleased to announce that research concerning their novel dual acting oxyntomodulin-based drug candidate SP-1373, has been selected for presentation at the American Diabetes Association's 77th Scientific Sessions. (Sunday Jun 11, 2017 12:00 PM - 1:00 PM, Poster 322-LB in category 22-A, Obesity-Animal)

"Type 2 diabetes, obesity and non-alcoholic steatohepatitis are major medical problems that are still in need of additional therapeutics. Spitfire Pharma LLC has been interested in harnessing the beneficial effects of the body's natural dual acting hormone oxyntomodulin (GLP-1/glucagon dual receptor agonist). A successful drug of this nature could add to the toolkit of physicians caring for such patients," said Dr. Andrew J. Perlman, Spitfire's Chief Medical Officer.

About Spitfire Pharma, Inc. 
Spitfire Pharma, Inc., is a "virtual" company which was created to hold the ownership of the SP-1373 development program. Spitfire is funded by Velocity Pharmaceutical Holdings, LLC (VPD). The SP-1373 development program is managed under contract by VPD. 

About Velocity Pharmaceutical Development, LLC 
VPD is a pharmaceutical development organization dedicated to rapidly advancing promising drug candidates to clinical proof of concept using a highly virtual management model. VPD seeks to acquire promising drug candidates, generally within a year of their entering human clinical trials or after initial human clinical data have been generated. VPD then manages a development program for each drug candidate intended to generate convincing human proof of concept data (generally by conducting a phase 2 clinical trial). Following successful human proof of concept, VPD then seeks a large pharmaceutical company acquirer for each program. VPD is staffed by a seasoned team of clinical drug developers with expertise identifying attractive drug candidates, target markets, and designing and managing outsourced clinical trials. This expert team manages multiple single asset companies to remove the costly overhead and misaligned incentives present in traditional biotechnology company structures. VPD believes this new capital-efficient model will yield attractive new drugs to treat patients with significant unmet clinical needs. The company is located in South San Francisco, California. More information is available at www.vpd.net

About Velocity Pharmaceutical Holdings, LLC 
Velocity Pharmaceutical Holdings, LLC, is an entity funded by Presidio Partners that makes investments in highly virtual, project-focused pharmaceutical development companies that are managed by Velocity Pharmaceutical Development, LLC. More information is available at www.vpd.net and www.presidiopartners.com

Contact
Leslie Loven
1-415-524-7326
leslie@vpd.net

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/spitfire-pharma-inc-will-present-body-weight-liver-weight-and-glucose-regulation-data-on-the-glp-1glucagon-dual-agonist-sp-1373-at-the-american-diabetes-associations-77th-scientific-sessions-300437782.html


'/>"/>
SOURCE Spitfire Pharma, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. NovoBioPharma, Partnership of Top Life Science Experts, Launches
2. Todays Research: Inovio Pharma, Sequenom, Peregrine Pharma, Onyx Pharma, and Optimer Pharma
3. Stipulation Of Dismissal Of Claims By Plaintiff Cornerstone Biopharma, Inc.
4. Todays Research: Delcath Systems, Astex Pharma, BioMarin Pharma, and Akorn
5. Pre-Market Analysis: MannKind, Galena Biopharma, Ariad Pharma, and Novavax
6. Medac Pharma, Inc. Announces Multiple Poster Presentations During the 2013 ACR/ARHP Annual Meeting
7. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims That the Merger May Not Be in the Best Interest of Investors of ViroPharma, Inc. - VPHM
8. Products Recall, Stock Price Updates, Technology Solution Deployment, Update on Extension Trial, and Donations - Research Report on Alexion Pharma, Questcor, BioMarin Pharma, Allscripts, and Prana
9. Positive Trial Results, Completed Acquisitions, and Clearances - Research Report on Dyax, IPC, Array BioPharma, Lexicon Pharmaceuticals, and Wright Medical
10. Healthcare Companies Report Conference Presentation Schedule, Stock Price Updates, and Clinical Study Results - Research Report on Medivation, Envision Healthcare, Fonar, Idera Pharma, and Neurocrine
11. Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 million ... continuing operations Second-quarter 2017 ... million Second-quarter 2017 Sterile ... Second-quarter 2017 adjusted diluted earnings ... to $0.93 Second-quarter 2017 ...
(Date:8/7/2017)... , Aug. 7, 2017 Zimmer Biomet Holdings, Inc. ... today announced that its Board of Directors has approved the ... third quarter of 2017. ... on or about October 27, 2017 to stockholders of record ... Future declarations of dividends are subject to approval of the ...
(Date:8/7/2017)...  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent ... 30, 2017.  All comparisons, unless otherwise noted, are to the ... Second Quarter 2017 Highlights include: ... increase of 3.5% Total prescriptions dispensed of ... 7.5% versus 7.6% Gross profit per ...
Breaking Medicine Technology:
(Date:8/19/2017)... ... 19, 2017 , ... Curl Keeper® is excited to announce that the H2O ... 2017 Award for the second year in a row. The H2O Bottle, a refillable ... voted Best Moisturizer for Type 2 Wavies and Best Refresher for Type 2 Wavies ...
(Date:8/19/2017)... ... August 19, 2017 , ... ... has joined its Orlando location as an interventional pain management physician. He brings ... on the treatment of migraine headaches, and significant experience in spinal cord stimulation ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... Immediate Release                Contact: Julian Teixeira, August 18, 2017                    202-478-8564 / jteixeira@thenc.org , ... from their Fathers , Contrary to a father’s perception, ...
(Date:8/18/2017)... ... 18, 2017 , ... Mediaplanet today announces the launch of ... and highlighting the importance of proactive eye and ear health. The campaign focuses ... innovations in hearing aid technology. , In this issue, the American Speech-Language-Hearing ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... asset protection assistance to communities in North-Central West Virginia, is embarking on a ... at-risk boys in the area. , The Chestnut Mountain Ranch (CMR) is a ...
Breaking Medicine News(10 mins):